ReviewCNS neuroscience & therapeutics2018
Cholinesterase targeting by polyphenols: A therapeutic approach for the treatment of Alzheimer's disease.
Review in CNS neuroscience & therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 1 synthesis or guideline pooled it, 178 citations in OpenAlex.
- Polyphenol Health Effects on Cardiovascular and Neurodegenerative Disorders: A Review and Meta-Analysis.International journal of molecular sciences · 2019Pooled it
- Phytochemical Characterization ofFood science & nutrition · 2026Article
- Bioactivity assessment and LC-MS/MS-based phenolic characterization of Gypsophila pilosa.Scientific reports · 2026Article
- Non-solvent cinnamic acid-based gel patch for transdermal drug delivery.Journal of advanced research · 2026Article
- Antioxidant, Anti-Cholinesterase, and Neuroprotective Properties ofAntioxidants (Basel, Switzerland) · 2026Article
- Characterisation of Dandelion Polyphenols and Their In Vitro Neuroprotective Effects During Simulated Digestion.Foods (Basel, Switzerland) · 2026Article
- Polyphenols and Neurodegenerative Diseases: Knowledge-Mining Insights, Mechanistic Evidence, and Emerging Nutritional Applications.Nutrients · 2026Review
- Chemical Profiling and Multi-Target Bioactivities of Erodium guttatum From Northeastern Algeria: LC-MS/MS and Molecular Docking Insights.Chemistry & biodiversity · 2026Article
- Antibiotic-Induced Gut Dysbiosis Modulates Alzheimer's Disease-Associated Gene Expression and Protein Aggregation in 3xTg-AD Mice via the Gut-Brain Axis.Brain and behavior · 2025Article
- ExploringLife (Basel, Switzerland) · 2025Article
- The Therapeutic Potential of Butyrate and Lauric Acid in Modulating Glial and Neuronal Activity in Alzheimer's Disease.Nutrients · 2025Review
- Development of a Guava Jelly Drink with Potential Antioxidant, Anti-Inflammation, Neurotransmitter, and Gut Microbiota Benefits.Foods (Basel, Switzerland) · 2025Article
- Bioactive Potential of BalkanMicroorganisms · 2025Article
- AChE Inhibition Capability of Nanogels Derived from Natural Molecules: Tannic Acid and Lysine for Alzheimer's Disease.Pharmaceutics · 2025Article
- Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer's Treatment: Systematic Review.Brain sciences · 2025Review
- Synthesis and Neurobehavioral Evaluation of a Potent Multitargeted Inhibitor for the Treatment of Alzheimer's Disease.Molecular neurobiology · 2025Article
- The influence of different drying techniques on polyphenols profile (LC-MS-PDA-Q/TOF) of peach fruit and their pro-health properties by in vitro.Scientific reports · 2025Article
- Novel Emerging Targets Identification in Reducing Risk of Alzheimer's Disease.Central nervous system agents in medicinal chemistry · 2025Review
- Article
- The effects of fermentation by different species of lactic acid bacteria on betalains and polyphenol profile and in vitro bioactive potential of red beetroot juice.Journal of food and drug analysis · 2024Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive irreversible neurodegenerative disorder characterized by excessive deposition of β-amyloid (Aβ) oligomers, and neurofibrillary tangles (NFTs), comprising of hyperphosphorylated tau proteins. The cholinergic system has been suggested as the earliest and most affected molecular mechanism that describes AD pathophysiology. Moreover, cholinesterase inhibitors (ChEIs) are the potential class of drugs that can amplify cholinergic activity to improve cognition and global performance and reduce psychiatric and behavioral disturbances. Approximately, 60%-80% of all cases of dementia in the world are patients with AD. In view of the continuous rise of this disease especially in the aged population, there is a dire need to come up with a novel compound and/or mixture that could work against this devastating disease. In this regard, the best is to rely on natural compounds rather than synthetic ones, because natural compounds are easily available, cost-effective, and comparatively less toxic. To serve this purpose, lately, scientific community has started exploring the possibility of using different polyphenols either solitary or in combination that can serve as therapeutics against AD. In the current article, we have summarized the role of various polyphenols, namely quercetin, resveratrol, curcumin, gallocatechins, cinnamic acid, caffeine, and caffeic acid as an inhibitor of cholinesterase for the treatment of AD. We have also tried to uncover the mechanistic insight on the action of these polyphenols against AD pathogenicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.